Incyteの空売り状況は、投資家がIncyteの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Incyte (NASDAQ:INCY) 株価情報, 空売り情報

INCYTE CORP

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Corp

Top U.S. technology multinationals, which have been the biggest beneficiaries of globalization, come to the fore as tariffs could heavily impact the cost of the goods sold by these firms.
What Happened: The data shared by Gina Martin Adams, the chief equity strategist and global director of equity strategy at Bloomberg Intelligence, shows the top tech companies in the U.S. that are likely to be impacted by <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted">tariffs announced</a> by President Donald Trump on Wednesday.
These firms &#8220;may suffer the most as tariffs spark trade turmoil and threaten the long-expanding margin domination of American companies,&#8221; explains Adams.
The graphic shared by her shows that <a href="https://www.benzinga.com/news/legal/25/04/44620411/mark-zuckerberg-led-meta-set-to-face-truth-at-senate-hearing-over-china-operations-and-communist-party-censorship-efforts">Mark Zuckerberg</a>&#8216;s Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) spends less than 10% of the total amount required for them to produce their products and services in the U.S., making it the most vulnerable to tariffs.
The top 10 firms also include Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>).
Adams says that these firms could face more challenges in the wake of retaliation by other countries, further influencing the global supply chain. &#8220;White House tariffs may only be the start, as retaliations further strain global supply chains,&#8221; she adds.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">US multinationals, arguably the biggest driver and beneficiary of globalization, may suffer most as tariffs spark trade turmoil and threaten margin domination of American companies. White House tariffs may only be the start, as retaliations further strain global supply chains. <a href="https://t.co/kbopS2fsT8">pic.twitter.com/kbopS2fsT8</a>
&mdash; Gina Martin Adams (@GinaMartinAdams) <a href="https://twitter.com/GinaMartinAdams/status/1907580802222690759?ref_src=twsrc%5Etfw">April 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44602836/tesla-short-interest-soars-to-2116-making-it-the-4th-largest-shorted-stock-heres-what-its-charts-are-indicating">Tesla Short Interest Soars To 21.16%, Making It 4th Most Shorted Stock Currently: Here&#8217;s What Its Charts Indicate</a>
Why It Matters: According to Adams, &#8220;Contrary to popular belief, mega-cap U.S. tech may be at considerable risk, with extremely high valuations and assumptions that margin moats will remain intact.
Companies with high facilities exposure and elevated cost of goods sold outside the U.S. face the greatest direct threats in the short run, while those with elevated revenue exposure are not immune.&#8221;
However, she adds, &#8220;Non-domestic stocks and defensive U.S. sectors may provide some haven as U.S. companies adjust to the new regime.&#8221;
Wedbush&#8217;s Daniel Ives adds that &#8220;Negotiations the only option at this point for White House.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We would characterize this slate of tariffs as &quot;worse than the worst case scenario&quot; the Street was fearing. The biggest focus will be the China 34% tariff and Taiwan 32% and how this impacts supply chain and demand. Negotiations the only option at this point for White House.
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1907611902047338791?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Whereas, Craig Shapiro of Bear Trap Reports contends by saying that Trump isn&#8217;t looking for concessions from trading partners, but &#8220;wants/needs the tariff revenues to help plug the fiscal deficit budget hole.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">What the market fails to realize is that Trump doesn&#39;t want concessions from trading partners. He wants/needs the tariff revenues to help plug the fiscal deficit budget hole <a href="https://t.co/nQf82Q2Zan">https://t.co/nQf82Q2Zan</a>
&mdash; Craig Shapiro (@ces921) <a href="https://twitter.com/ces921/status/1905609335599698141?ref_src=twsrc%5Etfw">March 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Here&#8217;s how these top 10 firms listed by Adams have performed.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Companies</td>
<td>Wednesday After-Hours</td>
<td>YTD</td>
<td>One Year</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>-4.83%</td>
<td>-2.55%</td>
<td>15.23%</td>
</tr>
<tr>
<td>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>)</td>
<td>-11.85%</td>
<td>-42.32%</td>
<td>-21.41%</td>
</tr>
<tr>
<td>Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)</td>
<td>-3.74%</td>
<td>-10.36%</td>
<td>12.69%</td>
</tr>
<tr>
<td>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>-5.79%</td>
<td>-14.65%</td>
<td>-43.04%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-7.14%</td>
<td>-8.19%</td>
<td>31.97%</td>
</tr>
<tr>
<td>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</td>
<td>-0.64%</td>
<td>23.26%</td>
<td>59.80%</td>
</tr>
<tr>
<td>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-3.32%</td>
<td>-15.23%</td>
<td>-43.94%</td>
</tr>
<tr>
<td>Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</td>
<td>0.02%</td>
<td>11.27%</td>
<td>4.44%</td>
</tr>
<tr>
<td>T-Mobile Us Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)</td>
<td>-2.68%</td>
<td>20.51%</td>
<td>62.05%</td>
</tr>
<tr>
<td>Best Buy Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>-8.99%</td>
<td>-12.12%</td>
<td>4.51%</td>
</tr>
</tbody>
</table>
</figure>
Ahead of the tariff announcements on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in trade. The SPY was up 0.63% to $564.52, while the QQQ advanced 0.73% to $476.15, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Thursday, the <a href="https://www.benzinga.com/markets/equities/25/04/44620686/sp-500-nasdaq-futures-plunge-over-3-as-trumps-reciprocal-tariff-plan-hits-market-confidence">futures</a> of the Dow Jones index dropped 2.25%, whereas the S&amp;P 500 and Nasdaq 100 indices also slumped by 3.02% and 3.52%, respectively.
Read Next:
<ul>
<li><a style="font-weight: bold;" href="https://www.benzinga.com/25/04/44600269/mark-cuban-argues-ais-new-sht-will-drive-growth-not-deflation">Mark Cuban Dismisses Concerns of AI Causing Deflation, Calls It The &#8220;Greatest Growth And Productivity Engine Ever&#8221;</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Equities

Government

Market Summary

News

Futures

Economics

Markets

Tech

ETFs

AAPL

DECK

INCY

TMUS

Meta, AMD, Apple, AT&T Among Biggest US Tech Giants That 'May Suffer The Most' As Tariffs Spark Trade Turmoil: Here's Why

Morgan Stanley analyst Vikram Purohit maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Equal-Weight and lowers the price target from $69 to $65.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $65

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares dipped 15.38% after UBS downgraded the stock from Buy to Neutral and <a href="https://www.benzinga.com/quote/beke/analyst-ratings" target="_blank" rel="noreferrer noopener">announced a price forecast of $24.5</a>.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock fell 9.76%. The stock briefly surged after Google announced an expanded partnership with Reddit, aiming to integrate Reddit content more <a href="https://www.benzinga.com//node/44369039" target="_blank" rel="noreferrer noopener">effectively across Google's products</a>.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock dived 8.75% after reporting topline results from two Phase 3 clinical trials of Povorcitinib in <a href="https://www.benzinga.com//node/44356786" target="_blank" rel="noreferrer noopener">patients with Hidradenitis Suppurativa</a>. William Blair and Guggenheim downgraded the stock, and Truist Securities cut its <a href="https://www.benzinga.com/quote/incy/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $74 to $72</a>.</li>
<li>James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares decreased 8.39%.</li>
<li>XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares dipped 8.13% after the company reported a <a href="https://www.benzinga.com//node/44373548" target="_blank" rel="noreferrer noopener">fourth-quarter adjusted EPS miss</a>.</li>
<li>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) shares decreased 7.63% after the company issued first-quarter adjusted<a href="https://www.benzinga.com//node/44426184" target="_blank" rel="noreferrer noopener"> EPS guidance below estimates</a>.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) stock fell 7.22%. The company said it is entering into a strategic partnership with Shield AI to deliver AI-powered autonomous solutions <a href="https://www.benzinga.com//node/44378015" target="_blank" rel="noreferrer noopener">for the U.S. government</a>.</li>
<li>Telus Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) shares decreased 7.07%.</li>
<li>Futu Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) stock declined 7.01%, probably after the People's Bank of China kept the one-year loan prime rate at 3.1% and the five-year rate at 3.6%. Policymakers are navigating how to support economic growth while stabilizing the yuan amid rising trade tensions.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares lost 6.02% last week after Rosenblatt cut its <a href="https://www.benzinga.com/quote/MU/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from</a> $250 to $200. The company reported <a href="https://www.benzinga.com//node/44425486" target="_blank" rel="noreferrer noopener">Q2 financial results</a>.</li>
</ol>
Image by Robert Way via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450329/robinhood-roku-and-shopify-are-among-top-10-large-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
</ul>

Large Cap

Movers

BEKE

FUTU

MRNA

RDDT

XPEV

XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs cut American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) price target from $367 to $330. Goldman Sachs analyst Ryan Nash maintained a Buy rating. American Express shares closed at $264.38 on Monday. See how other <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">analysts view this stock.</a></li>
<li>Morgan Stanley slashed the price target for SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from $27 to $20. Morgan Stanley analyst Hamza Fodderwala maintained an Equal-Weight rating. SentinelOne shares closed at $18.91 on Monday. <a href="https://www.benzinga.com/quote/S/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) price target from $22 to $19. Stifel analyst Steven Wieczynski maintained a Hold rating. PENN Entertainment shares closed at $17.26 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/PENN/analyst-ratings">view this stock</a>.</li>
<li>RBC Capital cut the price target for GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) from $453 to $445. RBC Capital analyst Christopher Dendrinos maintained an Outperform rating. GE Vernova shares closed at $331.96 on Monday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) from $270 to $235. Piper Sandler analyst Jason Bednar reiterated an Overweight rating. Align Technology shares closed at $169.59 on Monday. <a href="https://www.benzinga.com/quote/ALGNX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) price target from $125 to $115. Citigroup analyst Asiya Merchant maintained a Buy rating. Seagate shares settled at $90.51 on Monday. <a href="https://www.benzinga.com/quote/STX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital cut Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) price target from $23 to $20. Loop Capital analyst Rob Sanderson maintained a Buy rating. Lyft shares closed at $12.03 on Monday. <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities slashed Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) price target from $74 to $72. Truist Securities analyst Srikripa Devarakonda maintained a Hold rating. Incyte shares closed at $62.01 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/INCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital cut the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $440 to $320. RBC Capital analyst Tom Narayan maintained an Outperform rating. Tesla shares settled at $238.01 on Monday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc slashed Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $220 to $202. Keybanc analyst Justin Patterson maintained an Overweight rating. Alphabet shares closed at $164.29 on Monday. <a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

ALGN

GOOGL

LYFT

PENN

TSLA

Tesla To $320? Here Are 10 Top Analyst Forecasts For Tuesday

WIIM

Incyte shares are trading lower after William Blair and Guggenheim downgraded the stock and Truist Securities cut its price target from $74 to $72.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Lauren Lieberman downgraded the rating for PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and lowered the price target from $168 to $156. PepsiCo shares closed at $151.34 on Monday. <a href="https://www.benzinga.com/quote/pep/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim analyst Michael Schmidt downgraded Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintained the price target of $92. Incyte shares closed at $62.01 on Monday. <a href="https://www.benzinga.com/quote/INCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith downgraded TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) from Hold to Underperform and lowered the price target from $2.3 to $0.5. TPI Composites shares closed at $1.20 on Monday. <a href="https://www.benzinga.com/quote/TPIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Steven Fisher downgraded PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announced a $108 price target. PACCAR shares closed at $101.17 on Monday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Y Katherine Xu downgraded the rating for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform. Incyte shares closed at $62.01 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/ONCY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PEP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-1024x571.png" alt="" class="wp-image-829930" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18120202/image-151.png 1135w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Downgrades

PCAR

TPIC

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Hold and lowers the price target from $74 to $72.

Truist Securities Maintains Hold on Incyte, Lowers Price Target to $72

Guggenheim analyst Michael Schmidt downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintains the price target from $92 to $92.

Guggenheim Downgrades Incyte to Neutral, Maintains Price Target to $92

William Blair analyst Y Katherine Xu downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform.

William Blair Downgrades Incyte to Market Perform

On Monday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)&nbsp;released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">hidradenitis suppurativa (HS)</a>.
Hidradenitis suppurativa (HS), also known as acne inversa, is&nbsp;a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead to abscesses and scarring.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44245346/eli-lilly-incyte-partnered-fda-approved-drug-shows-encouraging-efficacy-in-adolescent-patients-with-patchy-hair-loss" rel="noreferrer noopener">Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss</a>
STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg).
A significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44352766/incyte-announces-positive-topline-results-from-two-phase-3-clinical-trials-of-povorcitinib-in-pati" rel="noreferrer noopener">draining tunnel count</a>.
The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was:
<ul>
<li>STOP-HS1: 45 mg: 40.2% vs. 29.7% [P=0.024]; 75 mg: 40.6% vs 29.7% [P=0.022].</li>
<li>STOP-HS2: 45 mg: 42.3% vs. 28.6% [P=0.004]; 75 mg: 42.3% vs. 28.6% [P=0.003].</li>
</ul>
Within a predefined subgroup of patients previously exposed to biologics, povorcitinib demonstrated greater differential efficacy (HiSCR50) when compared to placebo:
<ul>
<li>STOP-HS1: 45 mg: 34.2% vs. 21.9% [P=0.096]; 75 mg: 37.8% vs. 21.9% [P=0.037].</li>
<li>STOP-HS2: 45 mg: 45.0% vs. 19.5% [P=0.001]; 75 mg: 40.0% vs. 19.5% [P=0.005].</li>
</ul>
In addition, at Week 12, patients treated with povorcitinib achieved deep levels of clinical response with a greater proportion achieving HiSCR75, reduction in flares,&nbsp;&gt;3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30.
Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.
The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated.
Last week, Incyte revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis, a chronic skin condition characterized by <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44229321/incyte-releases-mixed-data-from-late-stage-opzelura-studies-in-skin-disease-characterized-by-itchy-firm-lumps" rel="noreferrer noopener">very itchy firm lumps</a>.
Price Action: INCY stock is down 11.90% at $59.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains</a></li>
</ul>

Biotech

Health Care

General

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.
Incyte shares dipped 15.3% to $57.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) dipped 12.1% to $44.01 in pre-market trading after gaining around 7% on Friday.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) fell 3.8% to $8.71 in pre-market trading.</li>
<li>Innventure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) slipped 3.3% to $7.62 in pre-market trading.</li>
<li>Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) fell 3% to $6.77 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1% to $ 247.77 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying">IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

AFRM

KMDA

NEOG

OMER

TYRA

USAR

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Incyte Corporation shares are trading lower after the company announced the results from its phase 3 STOP-HS clinical trial program of Povorcitinib for severe hidradenitis suppurativa.

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares increased by 107.6% to $5.19 during Monday's pre-market session. The company's market cap stands at $7.3 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 39.89% to $1.08. The company's market cap stands at $1.0 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares rose 19.85% to $1.63. The company's market cap stands at $258.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares moved upwards by 19.23% to $3.1. The company's market cap stands at $340.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares increased by 17.47% to $4.1. The market value of their outstanding shares is at $19.8 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 14.63% to $0.35. The market value of their outstanding shares is at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares decreased by 25.0% to $2.55 during Monday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock decreased by 22.29% to $0.55. The market value of their outstanding shares is at $41.1 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) shares fell 14.9% to $57.75. The market value of their outstanding shares is at $11.1 billion. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock declined by 12.55% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) shares declined by 11.65% to $9.71. The company's market cap stands at $425.0 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined by 9.46% to $0.34. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ANNX

CAPS

CNTX

MAZE

PALI

REVB

SHPH

SNTI

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/DTIL">pre-market trading</a>.
Precision BioSciences reported clearance of investigational new drug application by the U.S. FDA for first-in-class PBGENE-HBV designed to eliminate root cause of chronic hepatitis B.
Precision BioSciences shares climbed 10.8% to $5.58 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) gained 42.3% to $3.11 in pre-market trading.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) rose 36.7% to $0.1532 in pre-market trading after dipping 20% on Friday.</li>
<li>SES AI Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SES#NASDAQ">SES</a>) gained 29.1% to $0.5675 in pre-market trading after gaining 9% on Friday.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) gained 27.4% to $0.9837 in pre-market after gaining 13% on Friday.</li>
<li>Quantum-Si incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) gained 21.3% to $1.65 in pre-market trading after jumping 19% on Friday.</li>
<li>Inuvo, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INUV#NYSE">INUV</a>) gained 18.2% to $0.45 in pre-market trading.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) gained 16.5% to $0.9076 in pre-market trading.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose 15% to $8.15 after jumping 29% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) rose 11% to $1.61 in pre-market trading after jumping 14% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fold Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLD#NASDAQ">FLD</a>) shares fell 18.8% to $6.00 in pre-market trading after gaining around 8% on Friday.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 15.3% to $57.50 in pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.</li>
<li>Planet Green Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLAG#NYSE">PLAG</a>) dipped 14.4% to $1.71 in pre-market trading.</li>
<li>Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) declined 14.1% to $2.92 in pre-market trading.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Linkage Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares tumbled 13.5% to $0.1537 in pre-market trading after dipping over 22% on Friday.</li>
<li>Polar Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares fell 12.3% to $2.36 in pre-market trading.</li>
<li>Aspira Women&#8217;s Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) fell 10.8% to $0.1250 in today's pre-market trading after dipping over 8% on Friday. Aspira Women&#8217;s Health recently announced closing of $1.37 million private placement of convertible notes.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44350021/science-applications-international-getty-images-and-3-stocks-to-watch-heading-into-monday">Science Applications International, Getty Images And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>
Photo: Shutterstock

DRCT

DTIL

INUV

KULR

LGCB

NAOV

PLAG

POLA

QUBT

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested
- Favorable safety profile, with no safety concerns

Incyte Announced Topline Results From Its Phase 3 STOP-HS Clinical Trial Program Of Povorcitinib For Severe Hidradenitis Suppurativa, Both STOP-HS1 And STOP-HS2 Studies Met Their Primary Endpoint At Both Tested Doses

In the preceding three months, 6 analysts have released ratings for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $75.0, a high estimate of $88.00, and a low estimate of $68.00. A decline of 1.32% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741701634_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Incyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$77.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Incyte analyst ratings.</a>
<h2>Discovering Incyte: A Closer Look</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Breaking Down Incyte's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Incyte displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 16.32%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 17.07%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Incyte's ROE excels beyond industry benchmarks, reaching 6.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Incyte's ROA stands out, surpassing industry averages. With an impressive ROA of 3.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Incyte's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Citizens Capital Markets analyst Reni Benjamin reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Market Perform to Market Perform.

Reiteration

Citizens Capital Markets Reiterates Market Perform on Incyteto Market Perform

On Saturday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;and Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) said adolescent patients with severe alopecia areata (AA) treated with once-daily oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">eyelashes at Week 36</a>.
Findings from the Phase 3 BRAVE-AA-PEDS study were presented at the American Academy of Dermatology.
AA is an immune system condition that causes patchy hair loss on the scalp, face, and sometimes other body areas, which can <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44209669/lillys-baricitinib-delivered-high-rates-of-hair-regrowth-for-adolescents-with-severe-alopecia-area" rel="noreferrer noopener">progress over time</a>.
At Week 36:
<ul>
<li>60.0% of patients receiving baricitinib 4 mg and 36.9% of patients receiving baricitinib 2 mg saw at least a 50% improvement in their disease compared to 5.7% on placebo.</li>
<li>42.4% of patients receiving baricitinib 4 mg and 27.4% receiving baricitinib 2 mg achieved 80% or more scalp hair coverage, compared to 4.5% on placebo.</li>
<li>36.5% of patients receiving baricitinib 4 mg and 21.4% of patients receiving baricitinib 2 mg had 90% or more scalp hair coverage compared to 2.3% on placebo.</li>
<li>50.0% of patients receiving baricitinib 4 mg and 24.1% of patients receiving baricitinib 2 mg achieved significant eyebrow regrowth compared to 0% on placebo.</li>
<li>42.9% of patients receiving baricitinib 4 mg achieved significant eyelash regrowth, and 25.5% receiving baricitinib 2 mg saw improved eyelash regrowth, compared to 14.0% on placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44194539/eli-lillys-single-monthly-maintenance-shot-of-eczema-drug-shows-completely-clear-skin-at-3-years-in-50-of-trial-patients" rel="noreferrer noopener">Eli Lilly&#8217;s Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients</a>
Results achieved by adolescents at 36 weeks were comparable to those achieved by adults after 52 weeks of treatment, suggesting that hair regrowth may be faster in&nbsp;adolescents than in adults.
In the&nbsp;BRAVE-AA1 and BRAVE-AA2 studies, 40.9% of adult patients treated with baricitinib 4 mg and 21.2% of patients treated with baricitinib 2 mg achieved 80% or more scalp hair coverage at Week 52.
In 2022, the U.S. Food and Drug Administration (FDA) approved baricitinib, also known as Olumiant, for adult patients with severe AA.
Price Action: LLY stock is down 0.57% at $825.01, and INCY stock is up 0.89% at $71.76 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44242667/faraday-future-forays-into-new-york-ev-market-with-ff-91-20-launch" target="_blank" rel="noreferrer noopener">Faraday Future&#8217;s Big Apple Bet: Plans NY Expansion For Growth &amp; Brand Visibility</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

On Saturday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis (PN), a chronic skin condition characterized by very itchy firm lumps.
The data were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43597062/incyte-records-15-jump-in-2024-sales-on-strong-jakafi-opzelura-sales-says-2025-to-be-catalyst-rich-including-four-launches" rel="noreferrer noopener">Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches</a>
The TRuE-PN1 study met its primary endpoint, demonstrating that significantly more PN patients who applied ruxolitinib cream 1.5% versus vehicle control achieved a ≥4-point improvement from baseline in Worst-Itch Numeric Rating Scale (WI-NRS4) at Week 12 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44209194/incyte-announces-results-of-phase-3-clinical-trials-evaluating-ruxolitinib-cream-1-5-opzelura-in-p" rel="noreferrer noopener">(44.6% vs 20.6%)</a>.
Significant itch improvements were observed with ruxolitinib cream 1.5% versus vehicle control at Day 7 (22.4% vs. 8.0%), with numerical improvements versus vehicle control reported at earlier timepoints. Additionally, the TRuE-PN1 study met all key secondary endpoints, including:
<ul>
<li>Significantly more patients who applied ruxolitinib cream 1.5% versus vehicle control achieved an Investigator's Global Assessment for Stage of Chronic Prurigo Treatment Success (IGA-CPG-S-TS) at Week 12 (15.8% vs 3.9%).</li>
<li>Significantly more patients who applied ruxolitinib cream 1.5% versus vehicle control achieved overall treatment success (11.9% vs 2.9%).</li>
<li>Significantly more patients treated with ruxolitinib cream 1.5% versus vehicle control also achieved WI-NRS4 at Week 4 (29.7% vs 12.7%).</li>
</ul>
Additionally, topline data from the Phase 3 TRuE-PN2 clinical trial demonstrated a positive trend across all key secondary endpoints at Day 7 (nominal P-value &lt;0.05 for both).
While the primary endpoint favored ruxolitinib cream 1.5% versus vehicle, it did not reach statistical significance due to the high placebo response.
William Blair analyst Matt Phipps sees the TRuE-PN study results as disappointing, but they don't impact Incyte valuation since the model didn't factor in Opzelura's potential for PN. The company considers PN a smaller market for Opzelura, generating less than $1 billion, compared to its use for atopic dermatitis and vitiligo.
Price Action: INCY stock is up 0.92% at $71.44 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44224649/trevi-therapeutics-reveals-positive-data-from-mid-stage-study-for-chronic-cough-candidate-stock-jumps" target="_blank" rel="noreferrer noopener">Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps</a></li>
</ul>

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

<ul>
<li>Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg</li>
<li>Patients treated with&nbsp;baricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo</li>
<li>Positive data underscore Lilly's continued expansion across dermatologic conditions, with treatments that can improve outcomes for patients with the greatest need</li>
</ul>

Reported Saturday, Lilly And Incyte Present Late-Breaking Phase 3 Data Showing Baricitinib Significantly Improves Scalp, Eyebrow, And Eyelash Regrowth In Teens With AA

Press Releases

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Incyte to Present at Upcoming Investor Conferences

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

Comments

Incyte

空売り

Incyte (NASDAQ:INCY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル